T cell mediated immunity against influenza H5N1 nucleoprotein, matrix and hemagglutinin derived epitopes in H5N1 survivors and non-H5N1 subjects

Pirom Noisumdaeng 1, 2, 3, Thaneeya Roytrakul 4, Jarunee Prasertsopon 5, Phisanu Pooruk 6, Hatairat Lerdsamran 5, Susan Assanasen 7, Rungrueng Kitphati 8, Prasert Auewarakul 3, Pilaipan Puthavathana 3, 5 Corresp.

1 Faculty of Public Health, Thammasat University, Khlong Luang, Pathum Thani, Thailand
2 Thammasat University Research Unit in Modern Microbiology and Public Health Genomics, Thammasat University, Khlong Luang, Pathum Thani, Thailand
3 Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok-noi, Bangkok, Thailand
4 National Center for Genetic Engineering and Biotechnology, Khlong Luang, Pathum Thani, Thailand
5 Center for Research and Innovation, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand
6 The Government Pharmaceutical Organization, Biological Product Vaccine Production Plant, Kaengkhoi, Saraburi, Thailand
7 Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok-noi, Bangkok, Thailand
8 Ministry of Public Health, Nonthaburi, Thailand

Corresponding Author: Pilaipan Puthavathana
Email address: pilaipan.put@mahidol.edu

Background. Protection against the influenza virus by a specific antibody is relatively strain specific; meanwhile broader immunity may be conferred by cell-mediated immune response to the conserved epitopes across influenza virus subtypes. A universal broad-spectrum influenza vaccine which confronts not only seasonal influenza virus, but also avian influenza H5N1 virus is promising.

Methods. This study determined the specific and cross-reactive T cell responses against the highly pathogenic avian influenza A (H5N1) virus in four survivors and 33 non-H5N1 subjects including 10 H3N2 patients and 23 healthy individuals. Ex vivo IFN-γ ELISpot assay using overlapping peptides spanning the entire nucleoprotein (NP), matrix (M) and hemagglutinin (HA) derived from A/Thailand/1(KAN-1)/2004 (H5N1) virus was employed in adjunct with flow cytometry for determining T cell functions. Microneutralization (microNT) assay was performed to determine the status of previous H5N1 virus infection.

Results. IFN-γ ELISpot assay demonstrated that survivors nos. 1 and 2 had markedly higher T cell responses against H5N1 NP, M and HA epitopes than survivors nos. 3 and 4; and the magnitude of T cell responses against NP were higher than that of M and HA. Durability of the immunoreactivity persisted for as long as four years after disease onset. Upon stimulation by NP in IFN-γ ELISpot assay, 60% of H3N2 patients and 39% of healthy subjects exhibited a cross-reactive T cell response. The higher frequency and magnitude of responses in H3N2 patients may be due to blood collection at the convalescent phase of the patients. In H5N1 survivors, the effector peptide-specific T cells generated from bulk culture PBMCs by in vitro stimulation displayed a polyfunction by simultaneously producing IFN-γ and TNF-α, together with upregulation of CD107a in recognition of the target cells pulsed with peptide or infected with rVac-NP virus as investigated by flow cytometry.

Conclusions. This study provides an insight into the better understanding on the homosubtypic and heterosubtypic T cell-mediated immune responses in H5N1 survivors and non-H5N1 subjects. NP is an immunodominant target of cross-recognition owing to its high conservancy. Therefore, the development
of vaccine targeting the conserved NP may be a novel strategy for influenza vaccine design.
T cell mediated immunity against influenza H5N1 nucleoprotein, matrix and hemagglutinin derived epitopes in H5N1 survivors and non-H5N1 subjects

Pirom Noisumdaeng¹,²,³, Thaneeya Roytrakul⁴, Jarunee Prasertsopon⁵, Phisanu Pooruk⁶, Hatairat Lerdsamran⁵, Susan Assanasen⁷, Rungrueng Kitphati⁸, Prasert Auewarakul³ and Pilaipan Puthavathana³,⁵*

¹Faculty of Public Health, Thammasat University, Khlong Luang, Pathum Thani, Thailand
²Thammasat University Research Unit in Modern Microbiology and Public Health Genomics, Thammasat University, Khlong Luang, Pathum Thani, Thailand
³Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok-noi, Bangkok, Thailand
⁴National Center for Genetic Engineering and Biotechnology, Khlong Luang, Pathum Thani, Thailand
⁵Center for Research and Innovation, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand
⁶The Government Pharmaceutical Organization, Biological Product Vaccine Production Plant, Kaengkhoi, Saraburi, Thailand
⁷Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok-noi, Bangkok, Thailand
⁸Ministry of Public Health, Nonthaburi, Thailand

*Corresponding author:
Professor Emer. Pilaipan Puthavathana, Ph.D.
Abstract

Background. Protection against the influenza virus by a specific antibody is relatively strain specific; meanwhile broader immunity may be conferred by cell-mediated immune response to the conserved epitopes across influenza virus subtypes. A universal broad-spectrum influenza vaccine which confronts not only seasonal influenza virus, but also avian influenza H5N1 virus is promising.

Methods. This study determined the specific and cross-reactive T cell responses against the highly pathogenic avian influenza A (H5N1) virus in four survivors and 33 non-H5N1 subjects including 10 H3N2 patients and 23 healthy individuals. Ex vivo IFN-γ ELISpot assay using overlapping peptides spanning the entire nucleoprotein (NP), matrix (M) and hemagglutinin (HA) derived from A/Thailand/1(KAN-1)/2004 (H5N1) virus was employed in adjunct with flow cytometry for determining T cell functions. Microneutralization (microNT) assay was performed to determine the status of previous H5N1 virus infection.

Results. IFN-γ ELISpot assay demonstrated that survivors nos. 1 and 2 had markedly higher T cell responses against H5N1 NP, M and HA epitopes than survivors nos. 3 and 4; and the magnitude of T cell responses against NP were higher than that of M and HA. Durability of the immunoreactivity persisted for as long as four years after disease onset. Upon stimulation by NP in IFN-γ ELISpot assay, 60% of H3N2 patients and 39% of healthy subjects exhibited a cross-reactive T cell response. The higher frequency and magnitude of responses in H3N2 patients may be due to blood collection at the convalescent phase of the patients. In H5N1 survivors, the effector peptide-specific T cells generated from bulk culture PBMCs by in vitro stimulation displayed a
polyfunction by simultaneously producing IFN-γ and TNF-α, together with upregulation of CD107a in recognition of the target cells pulsed with peptide or infected with rVac-NP virus as investigated by flow cytometry.

Conclusions. This study provides an insight into the better understanding on the homosubtypic and heterosubtypic T cell-mediated immune responses in H5N1 survivors and non-H5N1 subjects. NP is an immunodominant target of cross-recognition owing to its high conservancy. Therefore, the development of vaccine targeting the conserved NP may be a novel strategy for influenza vaccine design.

Introduction

Influenza A virus infection is common in a wide range of avian and mammalian hosts (Webster et al., 1992; Horimoto & Kawaoka, 2005; Taubenberger & Kash, 2010; Long et al., 2019). Some avian influenza A virus subtypes, i.e., H5N1, H5N6, H7N7, H7N9 and H9N2, are able to cross the species barrier and infect humans (Wong & Yuen, 2006; Abdel-Ghafar et al., 2008; Yu et al., 2013; Puzelli et al., 2014; Pan et al., 2016; Peacock et al., 2019). Among these avian influenza subtypes, the H5N1 highly pathogenic avian influenza (HPAI) virus is the most virulent and the most fatal in humans and animals (Peiris, de Jong & Guan, 2007; Korteweg & Gu, 2008). The first outbreak of the H5N1 HPAI virus in humans occurred in Hong Kong in 1997. Its re-emergence in 2003 affected several countries in various continents, in particular, the Asia-Pacific region (Chan, 2002; Horimoto & Kawaoka, 2005; Peiris, de Jong & Guan, 2007). From 2003 to 10 July 2020, the World Health Organization (WHO) reported a cumulative number of 861 human cases with 455 deaths leading to the fatality rate of approximately 53% (WHO, 2020).

A person infected with the H5N1 HPAI virus mostly exhibits severe pneumonia, while
asymptomatic infection or mild illness was scant (Hinjoy et al., 2008; Le et al., 2013). Almost of the cases contracted the H5N1 virus infection through contact with sick or dead poultry. Rare cases of person-to-person transmission have been documented (Ungchusak et al., 2005). Interestingly, nearly all villagers living in the H5N1 outbreak areas are naïve to this virus infection (Hinjoy et al., 2008; Dejpichai et al., 2009), which anticipated that their immune system is naïve to this virus subtype.

There were several studies on the immune responses to H5N1 virus infection based on the in vitro or ex vivo system of animal origins (O'Neill et al., 2000; Seo & Webster, 2001; Seo, Peiris & Webster, 2002; Droebner et al., 2008; Sawai et al., 2008; Galli et al., 2009; Richards, Chaves & Sant, 2009; van et al., 2010; Rimmelzwaan & Katz, 2013; Lin et al., 2013; Ross et al., 2014; Park et al., 2014; Koutsakos, Kedzierska & Subbarao, 2019). Conversely, there is limited information on the immune responses against H5N1 virus infection in humans, particularly in terms of cell-mediated immunity (CMI) which plays an essential role on viral clearance by eliminating the virus-infected cells (Boon et al., 2004; Thomas et al., 2006; Mbawuike, Zhang & Couch, 2007; Rimmelzwaan & Katz, 2013; Koutsakos, Kedzierska & Subbarao, 2019). Several studies demonstrated that a majority of T cells specific to the seasonal H3N2 or H1N1 influenza virus recognize a variety of the viral proteins: nucleoprotein (NP), matrix (M), polymerase (PB1, PB2, PA), hemagglutinin (HA), neuraminidase (NA) and nonstructural (NS) proteins (Assarsson et al., 2008; Gioia et al., 2008; Kreijtz et al., 2008; Lee et al., 2008; Roti et al., 2008; Babon et al., 2009). The CD4⁺ and CD8⁺ T cells which targeted the seasonal influenza viral proteins also cross-recognized the internal conserved epitopes in H5N1 proteins: PB1, PB2, PA, NS, and in particular, the NP and M which are the immunodominant targets (Assarsson et al., 2008; Gioia et al., 2008; Kreijtz et al., 2008; Lee et al., 2008; Roti et al., 2008; Babon et al., 2009). Furthermore, the cross-
reactive memory CD4$^+$ T cells recognized the variable surface glycoprotein HA and NA (Roti et al., 2008). Nevertheless, this information was generated by using immune cells from healthy donors due to an inability to access the blood specimens from H5N1 patients. Therefore, the information obtained may not represent the immune response developed after H5N1 natural infection.

In this study, we assessed the T cell response to H5N1 NP, M, and HA epitopes using archival peripheral blood mononuclear cells (PBMCs) from individuals who recovered from H5N1 HPAI viral infections from 2004 to 2005 using flow cytometry and IFN-γ ELISpot assay. Moreover, we investigated the cross-reactive T cell response to H5N1 proteins in individuals who recovered from the H3N2 influenza virus infection. Our study may aid the design of a candidate T cell-based universal vaccine for broad-viral subtype protection.

Materials and Methods

Ethical issue

This study was approved by Institutional Review Boards from the Faculty of Medicine Siriraj Hospital, Mahidol University, under approval number Si213/2005. Informed consent was obtained from all non-H5N1 individuals and H5N1 survivors or their parents for participation in this study (Kitphati et al., 2009; Noisumdaeng et al., 2014).

Human subjects and blood specimen

Sera, plasma and peripheral blood mononuclear cells (PBMCs) were obtained from 37 participants including four H5N1 Thai survivors, 10 H3N2 patients and 23 healthy individuals (Kitphati et al., 2009; Noisumdaeng et al., 2013; Noisumdaeng et al., 2014). Survivor nos. 1 and
2 were adults, while survivor nos. 3 and 4 were young children. All of them were infected with H5N1 clade 1 virus. A total of 20 sequential blood samples were collected from these survivors at intervals for up to four years after disease onset (Kitphati et al., 2009). The demographic data of the H5N1 survivors and time at blood specimen collection are shown in supplementary Table S1A. The H3N2 patients were diagnosed by real time reverse transcription-polymerase chain reaction (real time RT-PCR), and virus isolation together with serodiagnosis when possible. Demographic data of non-H5N1 infected subjects is presented in supplementary Table S1B. Sera and plasma samples were kept frozen at -20°C until used. PBMCs were separated from anti-coagulated blood using Ficoll-Hypaque, (IsoPrep, Robbins Scientific Corporation, Sunnyvale, CA) density gradient centrifugation and stored in a freezing medium containing 10% DMSO (Sigma, MO) in fetal bovine serum (FBS) (Gibco®, NY) and cryopreserved in liquid nitrogen.

Recombinant vaccinia viruses

Recombinant vaccinia virus carrying H5N1 NP gene inserted in the pSC11 plasmid backbone (rVac-NP virus) or the recombinant virus carrying only the pSC11 backbone (rVac-pSC11 virus) were constructed in our laboratory. The viruses were propagated and titrated in Thymidine kinase negative (TK-) cells maintained in Dulbecco’s modified eagle medium (DMEM) (Gibco) supplemented with 10% FBS plus penicillin and streptomycin (Noisumdaeng et al., 2013; Noisumdaeng et al., 2014). The virus stocks were kept at -80°C until used.

Microneutralization (microNT) assay for antibody detection

ELISA-based microNT assay was carried out for detecting neutralizing antibodies against the A/Thailand/1(KAN-1)/2004 (H5N1) clade 1 (KAN-1 virus), A/Thailand/Siriraj-Rama-
TT/2004 [A/New Caledonia/20/1999 (H1N1)-like virus], and A/Siriraj ICRC/SI-154/2008 [A/Brisbane/10/2007 (H3N2)-like virus]. The assay protocol was described previously (Kitphati et al., 2009; Lerdsamran et al., 2011; Noisumdaeng et al., 2014).

Designing the overlapping peptides and peptide-pool matrix

Overlapping peptides spanning the entire NP, M1, M2 and HA proteins of H5N1 KAN-1 virus (GenBank accession no., AAV35112, AAV35110, AAV35111 and AAS65615, respectively) were synthesized in the PEPscreen® custom peptide libraries format (Sigma-Genosys, Singapore). According to supplementary Table S2, the amino acid sequence identities of each protein were conserved among various H5N1 viruses circulating in Thailand during the study period. According to the manufacturer, all peptides were analyzed by MALDI-TOF mass spectrometry and their average crude purity is greater than 70%. Each peptide was 20 amino acids long with 10 amino acid residues overlapping, except the last peptide of the protein which may be shorter. There were a total of 49 NP peptides, 25 M1 peptides, 10 M2 peptides and 56 HA peptides as shown in supplementary Tables S3A-S3C. Peptide powder was dissolved in dimethyl sulfoxide (DMSO, Sigma) to the concentration of 50 mg/ml, then aliquot and kept at -80°C. The concentrate peptide solution was further diluted in serum-free Roswell Park Memorial Institute 1640 medium (RPMI, Gibco) to the concentration of 2.5 mg/ml and stored at -80°C in aliquots. These peptides were mixed into individual pools according to the two-dimensional matrix system as shown in supplementary Tables S3D-S3F. Each peptide pool contained an individual peptide at working concentration of 40 µg/ml. There were a total of 14 pools (A1-A7 and B1-B7) for NP, 12 pools (A1-A6 and B1-B6) for M and 15 pools (A1-A8 and B1-B7) for HA. The DMSO concentration in each assay was less than 0.1% (v/v).
Ex vivo IFN-γ enzyme-linked immunospot (ELISpot) assay

IFN-γ ELISpot assay was performed to demonstrate the T cell responses against H5N1-derived peptides among H5N1 survivors and non-H5N1 subjects. A 96-well polyvinylidene difluoride (PVDF) ELISPOT plate (Multiscreen™ IP, MAIPS4510, Millipore, USA) was coated with mouse monoclonal anti-human IFN-γ 1-D1K (Mabtech AB, Stockholm, Sweden) at a concentration of 15 µg/ml overnight at 4°C, followed by blocking with RPMI supplemented with 10% FBS for 2 hours. After the blocking solution was discarded, the PBMC suspensions were added at the concentration of 3x10⁵ cells/100 µl/well. Thereafter, peptide pool at a final concentration of 4 µg/ml (for screening of T cell activity) or individual peptide (for peptide specific activity of T cells) at a final concentration of 10 µg/ml was added into each well. PBMCs incubated with medium only served as the negative control, whereas PBMCs treated with 1 and 10 µg of phytohemagglutinin (PHA) (Sigma) served as the positive controls. After incubation for 14-16 hours, PBMCs were removed, and the plate was washed with 0.05% Tween-20 in PBS (PBST). The biotin conjugated-anti-IFN-γ (7-B6-1-biotin, Mabtech) was used as the primary antibody to bind the released IFN-γ absorbed on the membrane lining the plate bottom. Streptavidin-labelling alkaline phosphatase was used as the secondary antibody and followed by BCIP/NBT plus (Mabtech) as the chromogenic substrate. The reaction plate was incubated until purple spots were visible on the membrane, and then the reaction was terminated. The spots which represent the secreted IFN-γ producing T cells were counted and analyzed using a KS ELISpot version 4.11 program of an ELISpot plate reader (KS ELISpot, Zeiss, Munich, Germany). The T cell activity was considered positive when the number of spot forming cells (SFCs) in the reaction wells was at least two times greater than those of the negative control wells.
Functional assays of H5N1-specific T cells

The T cell functional assay was demonstrated by intracellular cytokine staining (ICS) and flow cytometry of peptide-specific polyclonal T cell lines (effector T cells) which were generated as bulk culture by stimulating the PBMCs with an individual specific peptide. The study design was shown in supplementary Fig. S1, and the detailed method was as followed:

- Establishment of Epstein-Barr virus (EBV) transformed B cell lines (TBCLs)

Autologous TBCLs were used as the target cells for T cell functional assay by flow cytometry. TBCLs were established by infecting PBMCs with EBV from supernatant of B95-8 culture in RPMI supplemented with 10% FBS and in the presence of cyclosporin A. Clumps of transformed B lymphocytes generally appeared after 2-3 weeks of infection. TBCLs could multiply indefinitely, a condition known as immortalization.

- Establishment and maintenance of peptide-specific T cell lines

A bulk culture of specific polyclonal T cell line was generated by stimulating PBMCs with peptide and used as a source of the effector T cells. Frozen PBMCs of an number of 5-10x10^6 cells were thawed and divided into two portions comprising 20% and 80% of total cells. The 20% portion were pulsed with 100 μg/ml of peptide before mixing with the 80% portion. The suspension of cell mixture was added into a 6-well culture plate at the amount of 2-3x10^6 cells/well in 10% NHS RPMI supplemented with 25 ng/ml IL-7 (Peprotec, USA) and 50 U/ml IL-2 (Chiron, Netherlands).

Clumps of proliferating T cells should be seen in the culture at approximately 2 weeks after cultivation, i.e., peptide-specific polyclonal T cell line was established. T cell lines were expanded
by stimulation with autologous gamma irradiated peptide-pulsed TBCLs plus irradiated allogeneic PBMCs (2,000 rad using cesium source).

- **Target cell preparation**

The peptide-pulsed autologous TBCLs or TBCLs infected with rVac-NP virus were used as the target cells or antigen presenting cells (APCs) for investigating the function of peptide-specific T cells by flow cytometry. The unpulsed TBCLs or TBCLs infected with rVac-pSC11 virus were used as the negative target cell control. Pellets of TBCLs were pulsed with 100 μg/ml of specific peptides for 1 hour, followed by washing and re-suspending with 10% FBS RPMI. For preparing recombinant vaccinia virus infected TBCLs, the cells were infected with rVac-NP or rVac-pSC11 virus at a multiplicity of infection (moi) of 3. After adsorption for 1 hour 30 minutes at 37°C, the infected cells were washed and re-sususpended with 2% FBS RPMI and incubated overnight prior to functional assay by flow cytometry.

- **Intracellular cytokine staining (ICS) by flow cytometry**

The flow cytometry assay comprised the FACS tubes of the polyclonal peptide-specific T cell lines (effector cells) stimulated with target cells (TBCLs pulsed with specific peptide or TBCLs infected with rVac-NP virus), and the control tubes including the effector cell alone, effector cells plus unpulsed TBCLs or effector cells plus rVac-pSC11 virus infected TBCLs. Staphylococcal enterotoxin B (SEB) was used as the positive stimulation control. Briefly, 1x10^5 effector cells were mixed with 1x10^6 target cells in a one ml volume (effector: target ratio of 1:10). The cell mixtures were incubated with anti-CD107a monoclonal antibody conjugated with FITC (BD Bioscience) for 2 hours before adding with the mixture of monensin and brefeldin A at the final concentration of 10 μg/ml, and further incubated for 5 hours. The cells were washed with FACS washing buffer (1% FBS, 0.5% NHS, 0.5 mM EDTA, 0.1% NaN_3 in PBS) and treated with
FACS Permeabilizing Solution II (BD Biosciences) for 15 minutes in the dark in order to fix and permeabilize the cells. Thereafter, the cells were washed and stained with a cocktail of monoclonal antibodies: anti-CD4 PerCP or anti-CD8 PerCP, anti-IFN-γ APC and anti-TNF-α PE monoclonal antibodies (BD Biosciences). The CD4⁺ or CD8⁺ T cell populations producing IFN-γ, TNF-α and upregulation of CD107a degranulation marker were analyzed by FACSCalibur™ instrument by using CellQuest™ program (BD Biosciences).

Data analysis
The data graphs on IFN-γ T cell responses in H5N1 survivors and non-H5N1 subjects were generated using GraphPad Prism software version 4.0. The difference in the magnitude of responses (SFCs/10⁶ PBMCs) between the H3N2 patients and healthy subjects was analyzed by Mann-Whitney U test. The statistically significant difference was obtained when the P-value was less than 0.05.

Results
Screening for T cell response against NP, M and HA in H5N1 survivors
Pool peptides derived from H5N1 NP, M or HA amino acid sequences were employed to screen for reactive T cell response in H5N1 survivors using IFN-γ ELISpot assay. The results showed that PBMCs from the four H5N1 survivors elicited T cell responses against NP, M and HA peptide pools as shown in Fig. 1A, 1B and 1C, respectively. The number of IFN-γ producing T cells stimulated by NP pooled peptides was higher than those of M and HA, which suggested that NP was more immunogenic in the induction of T cell responses. We also found that the T cell
response in adults (survivor nos. 1 and 2) was stronger than that in children (survivor nos. 3 and 4). The T cell reactivity against NP and M peptides persisted for as long as 4 years after onset of disease as followed that far (Fig. 1A and 1B). All four H5N1 survivors had markedly high neutralizing antibody titers against H5N1 virus as demonstrated by an ELISA-based microNT assay. Moreover, they also contained neutralizing antibodies to seasonal H1N1 and/or H3N2 viruses as shown in supplementary Table S1.

Determining the T cell activity against specific epitopes on NP, M and HA

Due to strong responses to pooled NP, M and HA peptides, H5N1 survivor nos. 1 and 2 were further identified for individual T cell specific epitopes by ELISpot assay. The major epitopes recognized by survivor no. 1 were NP1-20, NP111-130 (Fig. 2A, left panel), M1121-140, M1201-220 (Fig. 2A, middle panel) and HA461-480 (Fig. 2A, right panel); whereas survivor no. 2 recognized NP411-430 (Fig. 2B, left panel), M11-20, M191-110, M1241-252 (Fig. 2B, middle panel), HA41-60, HA251-270 and HA291-310 (Fig. 2B, right panel). However, the magnitude of responses to NP peptides was higher than those to M and HA peptides, indicating that NP is more immunogenic and putatively a highly immunogenic protein target for T cell responses. Based on serial PBMC samples, it was demonstrated that the reactivity of the peptide-reactive T cells could persist for at least 4 years after disease onset. The summary of magnitude and longevity of T cell responses are shown in supplementary Table S4.

Cross-reactive T cell responses against H5N1 NP peptides in non-H5N1 individuals

This study carried out the cross-reactive T cell response to H5N1 NP peptides in 33 non-H5N1 individuals, including PBMCs from convalescent blood samples of 10 H3N2 patients and
276 23 healthy individuals. These subjects were confirmed for their H5N1 seronegativity by microNT assay (supplementary Table S1B). PBMCs were tested against the 49 overlapping peptides spanning the entire H5N1 NP by IFN-γ ELISpot assay. The results demonstrated that the magnitude of total cross-reactive T cells varied considerably between individuals. The mean of ex vivo IFN-γ responses was 102 and 51 SFCs/10⁶ PBMCs in H3N2 patients and healthy subjects, respectively; and the mean of responses was statistically significant different between both groups (Mann-Whitney U test; p<0.05) (Fig. 3).

The ELISpot assay with individual candidate NP peptide was conducted to identify the peptide-specific reactivity. From a total of 33 non-H5N1 subjects, six (60%) of 10 H3N2 patients and nine (39%) of 23 healthy subjects responded to the stimulation by NP peptides derived from H5N1 KAN-1 virus. In total, 5 peptides were recognized, i.e., NP₁₁₁₋₁₃₀, NP₂₂₁₋₂₃₀, NP₃₁₁₋₃₃₀, NP₄₀₁₋₄₂₀ and NP₄₈₁₋₄₉₈ as indicated in Table 1. However, each responder recognized only 1 or 2 peptides.

H5N1 NP-specific T cells elicited cytokine production and cytotoxic function

The effector cells in bulk cultures of peptide-specific T cell lines (generated by clonal expansion of T cells after in vitro stimulation [IVS] of PBMCs from H5N1 survivors no. 1 with NP₁-₂₀ and survivors no.2 with NP₄₁₁₋₄₃₀ peptide) were investigated by flow cytometry for IFN-γ and TNF-α productions, and the upregulation of CD107a, the degranulating marker of cytotoxic function, and additionally their immunophenotypes. The result showed that both CD4⁺ and CD8⁺ T cells from survivor nos. 1 and 2 expressed IFN-γ⁺ and TNF-α⁺ in recognition to the target cells infected with rVac-NP virus or pulsed with NP₁-₂₀ (for survivor no.1) or NP₄₁₁₋₄₃₀ (for survivor no.2). Nevertheless, only CD8⁺ T cells sufficiently expressed CD107a⁺, while the expression level was poor for the CD4⁺T cells (Fig. 4, supplementary Fig. S2 and supplementary Table S5).
Identity of NP epitope sequences among different influenza virus subtypes

Amino acid sequences of the H5N1 NP peptides that were recognized by the H5N1 survivors and non-H5N1 subjects were aligned and analyzed for their identities with those derived from the human influenza viruses as shown in Table 2. The H5N1 NP\textsubscript{1-20} and NP\textsubscript{401-420} amino acid sequences were identical to those of the H1N1pdm virus, while the NP\textsubscript{111-130} and NP\textsubscript{221-240} were identical to the H3N2 virus. As such, the H5N1 cross-reactive T cells found in non-H5N1 subjects (NP\textsubscript{111-130}, NP\textsubscript{221-240}, NP\textsubscript{311-330}, NP\textsubscript{401-420}, and NP\textsubscript{481-498} peptides) might be generated from previous exposure to the common epitopes between the H5N1 virus and the seasonal H1N1 or H3N2 viruses. Cross reactivity for the NP\textsubscript{111-130} and NP\textsubscript{221-240} was found in higher frequency than the other peptides. Interestingly, the NP\textsubscript{411-430} (TFSVQRNLPERATIMAAFT) was a unique epitope recognized by H5N1 survivors only.

Discussion

Thailand reported 25 H5N1 infected cases with 17 deaths (fatality rate 68%) to WHO during the outbreak that lasted from 2004 to 2006. No H5N1 patient has occurred since then. We could access four of the eight survivors, whose sequential blood samples were collected at approximately six-month intervals. Using cryopreserved PBMC samples from four H5N1 survivors and 23 non-H5N1 subjects, the present study employed IFN-\(\gamma\) ELISpot assay and flow cytometry to investigate cell-mediated immune responses targeting NP, M and HA derived from HPAI H5N1 virus strain A/Thailand/1(KAN-1)/2004 (H5N1) (Pathavathana et al., 2005; Kitphati et al., 2009). Our analyses on the amino acid sequence identities of various H5N1 viruses isolated in Thailand between 2004 and 2008 against the KAN-1 virus showed that the peptides used were
relatively conserved across the circulating viruses during the study period. NP was the most conserved protein with the degree of identities varying from 99.1-100%, whereas the identities among M1, M2, and HA proteins ranging from 98.8-100%, 96.9-100%, and 98.7-99.8%, respectively. The study demonstrated that adult survivors (nos. 1 and 2) had stronger T cell response than the children survivors (nos. 3 and 4) which could be explained by few reasons: 1) adults were previously expose to the seasonal influenza virus infection or vaccination; therefore, the pre-existing cross-reactive T cells might be boosted after H5N1 infection, and also adding up with more number of H5N1-specific T cells; 2) young children generated a lower number of influenza virus-specific memory T cells compared to adults; or the memory T cells from children had shorter half-life; and 3) young children (survivor no. 3) who developed mild disease after H5N1 virus infection might generate a lower number of specific memory T cells than adult survivors who developed severe disease. It has been previously reported that the 2009 H1N1pdm patients who developed severe disease elicited higher levels of circulating influenza virus-specific CD4+ T cells to NP and M when compared to the cases with mild disease as measured by ELISpot assay (Zhao et al., 2012).

The total number of IFN-γ reactive T cells against NP was higher than that of M and HA as demonstrated in two H5N1 adult survivors by ELISpot assay using 20 mers-overlapping pooled peptides, which suggested that NP was more immunogenic in the induction of T cell response. NP is the most abundant viral protein synthesized in the infected cells. It contains several immunodominant epitopes that could stimulate both the humoral and cell-mediated immune responses. As such, NP was identified as the major target of subtype-specific and cross-subtypic CD4+ and cytotoxic CD8+ T lymphocytes as reported by several groups of previous investigators (Kreijtz et al., 2008; Lee et al., 2008; Rimmelzwaan & Katz, 2013; Roti et al., 2008). Our result of
the 1st round ELISpot assay using pooled peptides was confirmed by the 2nd round ELISpot assay using individual peptides. T cell responses could last longer than 4 years after disease onset for as far as the PBMC samples were available. Using individual peptide, our results showed that each survivor recognized different peptides, suggesting that their HLA or their repertoire of specific T cells were different.

Up until the present day, the H5N1-specific T cell epitopes are not well characterized due to the small number of H5N1 survivors. Powell, et al. (Powell et al., 2012) could identify three H5 HA-specific T cell epitopes (HA160-177, HA344-364 and HA439-456) from H5N1 asymptomatic cases; while Sun, et al. (Sun et al., 2010) could identify only one H5 HA-specific T cell epitope (HA205-214). However, our study was confined to the H5N1 NP peptides according to the limited amount of PBMCs available and the high immunogenicity of NP epitopes. Amino acid sequence identity of greater than 90% was found across NP proteins of various influenza virus subtypes (Noisumdaeng et al., 2014). Among 49 NP overlapping peptides, three peptides (NP1-20, NP111-130 and NP411-430) were identified among the four H5N1 survivors, and five peptides (NP111-130, NP221-230, NP311-330, NP401-420 and NP481-498) among 33 non-H5N1 subjects. Interestingly, only one peptide, NP111-130, could be identified in both H5N1 survivors and non-H5N1 subjects. Based on A/Viet Nam/CL26/2004 (H5N1) sequence, the study in healthy Vietnamese and English subjects demonstrated the cross-reactive CD4+ T cells against H5N1 NP221-238, NP404-420 and NP478-493 as determined by ELISpot assay (Lee et al., 2008). Moreover, the cross-reactive CD4+ T cells against H5N1 NP401-420 and NP113-132 were demonstrated in the healthy Caucasian descent based on A/Vietnam/1203/2004 H5N1 (VN1203) as determined by tetramer-guide epitope mapping. The NP401-420 was restricted to HLA-DR0404; while NP113-132 was restricted to HLA-DR1101 (Roti et
al., 2008). However, the NP epitope variants which could escape from the T cell recognition have been reported (Rimmelzwaan et al., 2004; Berkhoff et al., 2007).

We further investigated the effector functions and immunophenotypes of the NP peptide-specific T cells by flow cytometry. The NP$^{1-20}$ and NP$^{411-430}$ peptides could stimulate both CD4$^+$ and CD8$^+$ T cell subsets in survivors, leading to clonal expansion and a high degree of polyfunction by simultaneously producing IFN-$\gamma$ and TNF-$\alpha$, and together with an upregulation of CD107a in recognition of the target cells pulsed with peptide or infected with rVac-NP virus. Since our peptides are 20 amino acids long; they might bind to both HLA class I (optimal epitope are 8-12 amino acids long) and class II (optimal epitope are 12-18 amino acids long) and lead to activation of CD4$^+$ and CD8$^+$ memory T cells. It is implied that NP protein expressed in the rVac-NP virus infected TBCLs is naturally processed and presented in association with HLA to the effector T cells (Jameson, Cruz & Ennis, 1998). Importantly, it is uncertain that the induction of such polyfunctional T cell populations might be associated with the recovery from severe diseases in our H5N1 survivors. The amino acid sequences of the avian H5N1 internal proteins were closely identical to those of the seasonal H1N1, H3N2 and H1N1pdm viruses; exposure to seasonal influenza virus infection or vaccination can generate a pool of cross-reactive memory CD4$^+$ and CD8$^+$ T cells which are capable of recognizing a number of conserved internal proteins form avian H5N1 virus.

Conclusions

The broader vaccines that rely on the induction of T cell-based immunity against conserved epitopes would provide broader partial protection, restrict the viral diversity in the infected host and help lower severity and mortality against overwhelming pandemic influenza virus infection.
Our present study provides insight into a better understanding of the homosubtypic and heterosubtypic T cell-mediated immune responses against H5N1 virus in H5N1 survivors and non-H5N1 subjects. NP is an immunodominant target of cross-recognition owing to its high conservancy. Therefore, the development of vaccine targeting the conserved NP may be a novel strategy for influenza vaccine design.

Acknowledgements

We would like to thank all subjects who participated in the study. We thank all medical staff from Department of Disease Control, Ministry of Public Health for their help in specimen collection from H5N1 survivors and research assistants at Siriraj Influenza Cooperative Research Center, Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University for kindly supporting reagents, materials and techniques. P.N. specially thanks Thammasat University Research Unit in Modern Microbiology and Public Health Genomics, Thammasat University.

References

Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H, Sette A. 2008. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. *Journal of Virology* **82**(24):12241-51 DOI 10.1128/JVI.01563-08.

Babon JA, Cruz J, Orphin L, Pazoles P, Co MD, Ennis FA, Terajima M. 2009. Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. *Human Immunology* **70**(9):711-21 DOI 10.1016/j.humimm.2009.06.004.
Berkhoff EG, Geelhoed-Mieras MM, Verschuren EJ, van Baalen CA, Gruters RA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. 2007. The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro. *Clinical Experimental Immunology* 148(2):296-306 DOI 10.1111/j.1365-2249.2007.03340.x.

Boon AC, de Mutsert G, van Baarle D, Smith DJ, Lapedes AS, Fouchier RA, Sintnicolaas K, Osterhaus AD, Rimmelzwaan GF. 2004. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. *Journal of Immunology* 172(4):2453-60 DOI 10.4049/jimmunol.172.4.2453.

Chan PK. 2002. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. *Clinical Infectious Diseases* 1:34 Suppl 2:S58-S64 DOI 10.1086/338820.

Dejpichai R, Laosiritaworn Y, Phuthavathana P, Uyeki TM, O'Reilly M, Yampikulsakul N, Phurahong S, Poorak P, Prasertsopon J, Kularb R, Nateerom K, Sawanpanyalert N, Jiraphongs C. 2009. Seroprevalence of antibodies to avian influenza virus A (H5N1) among residents of villages with human cases, Thailand, 2005. *Emerging Infectious Diseases* 15(5):756-60 DOI 10.3201/eid1505.080316.

Droebner K, Haasbach E, Fuchs C, Weinzierl AO, Stevanovic S, Büttner M, Planz O. 2008. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. *Vaccine* 26(52):6965-74 DOI 10.1016/j.vaccine.2008.09.051.

Galli G, Medini D, Borgoni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G, Castellino F. 2009. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that
predicts long-term persistence of protective antibody levels. *Proceedings of the National Academy of Sciences of the United States of America.* 106(10):3877-82 DOI 10.1073/pnas.0813390106.

Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R, Agrati C, Squarcione S, Ippolito G, Puro V, Capobianchi MR, Poccia F. 2008. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. *Emerging Infectious Diseases* 14(1):121-8 DOI 10.3201/eid1401.061283.

Hinjoy S, Puthavathana P, Laosiritaworn Y, Limpakarnjanarat K, Pooruk P, Chuxnum T, Simmerman JM, Unghchusak K. 2008. Low frequency of infection with avian influenza virus (H5N1) among poultry farmers, Thailand, 2004. *Emerging Infectious Diseases* 14(3):499-501 DOI 10.3201/eid1403.070662.

Horimoto T, Kawaoka Y. 2005. Influenza: lessons from past pandemics, warnings from current incidents. *Nature Review Microbiology* 3(8):591-600 DOI 10.1038/nrmicro1208

Jameson J, Cruz J, Ennis FA. 1998. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. *Journal of Virology* 72(11):8682-9 DOI 10.1128/JVI.72.11.8682-8689.1998.

Kitphati R, Pooruk P, Lerdasamran H, Poosuwan S, Louisirirothanakul S, Auewarakul P, Chokphaibulkit K, Noisumdaeng P, Sawanpanyalert P, Puthavathana P. 2009. Kinetics and longevity of antibody response to influenza A H5N1 virus infection in humans. *Clinical and Vaccine Immunology* 16(7):978-81 DOI 10.1128/CVI.00062-09.

Korteweg C, Gu J. 2008. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. *The American Journal of Pathology* 172(5):1155-70 DOI 10.2353/ajpath.2008.070791.
Koutsakos M, Kedzierska K, Subbarao K. 2019. Immune responses to avian influenza viruses. *Journal of Immunology* **202**(2):382-91 DOI 10.4049/jimmunol.1801070.

Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. 2008. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. *Journal of Virology* **82**(11):5161-6 DOI 10.1128/JVI.02694-07.

Le MQ, Horby P, Fox A, Nguyen HT, Le Nguyen HK, Hoang PM, Nguyen KC, de Jong MD, Jeeninga RE, Rogier van Doorn H, Farrar J, Wertheim HF. 2013. Subclinical avian influenza A(H5N1) virus infection in human, Vietnam. *Emerging Infectious Diseases* **19**(10):1674-7 DOI 10.3201/eid1910.130730.

Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, Townsend AR, Askonas BA, Rowland-Jones S, Dong T. 2008. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. *The Journal Clinical Investigation* **118**(10):3478-90 DOI 10.1172/JCI32460.

Lerdsamran H, Pittayawonganon C, Pooruk P, Mungaomklang A, Iamsirithaworn S, Thongcharoen P, Kositanont U, Auewarakul P, Chokephaibulkit K, Oota S, Pongkankham W, Silaporn P, Komolsiri S, Noisumdaeng P, Chotpitayasunondh T, Sangsajja C, Wiriyarat W, Louisirirotchanakul S, Puthavathana P. 2011. Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population. *PLoS One* **6**(1):e16164 DOI 10.1371/journal.pone.0016164.
Lin HT, Chuang CC, Wu HL, Chu DM, Wang YC. 2013. Characterization of cross protection of swine-origin influenza virus (S-OIV) H1N1 and reassortant H5N1 influenza vaccine in BALB/c mice given a single-dose vaccination. *Journal of Biomedical Science* **20**(1):19 DOI 10.1186/1423-0127-20-19.

Long JS, Mistry B, Haslam SM, Barclay WS. 2019. Host and viral determinants of influenza A virus species specificity. *Nature Reviews Microbiology* **17**(2):67-81 DOI 10.1038/s41579-018-0115-z.

Mbawuike IN, Zhang Y, Couch RB. 2007. Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes. *Respiratory Research* **8**(1):44 DOI 10.1186/1465-9921-8-44.

Noisumdaeng P, Pooruk P, Kongchanagul A, Assanasen S, Kitphati R, Auewarakul P, Puthavathana P. 2013. Biological properties of H5 hemagglutinin expressed by vaccinia virus vector and its immunological reactivity with human sera. *Viral Immunology* **26**(1):49-59 DOI 10.1089/vim.2012.0055.

Noisumdaeng P, Pooruk P, Prasertsopon J, Assanasen S, Kitphati R, Auewarakul P, Puthavathana P. 2014. Homosubtypic and heterosubtypic antibodies against highly pathogenic avian influenza H5N1 recombinant proteins in H5N1 survivors and non-H5N1 subjects. *Virology* **454-455**:254-62 DOI 10.1016/j.virol.2014.02.024.

O’Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL. 2000. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. *The Journal of General Virology* **81**(Pt 11):2689-96 DOI 10.1099/0022-1317-81-11-2689.
Pan M, Gao R, Lv Q, Huang S, Zhou Z, Yang L, Li X, Zhao X, Zou X, Tong W, Mao S, Zou S, Bo H, Zhu X, Liu L, Yuan H, Zhang M, Wang D, Li Z, Zhao W, Ma M, Li Y, Li T, Yang H, Xu J, Zhou L, Zhou X, Tang W, Song Y, Chen T, Bai T, Zhou J, Wang D, Wu G, Li D, Feng Z, Gao GF, Wang Y, He S, Shu Y. 2016. Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: Virological and clinical findings. Journal of Infection 72(1):52-9 DOI 10.1016/j.jinf.2015.06.009.

Park SJ, Kim EH, Pascua PNQ, Kwon HI, Lim GJ, Decano A, Kim SM, Song MK, Shin EC, Choi YK. 2014. Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. Journal of General Virology 95(Pt 4):793-798 DOI 10.1099/vir.0.058636-0.

Peacock THP, James J, Sealy JE, Iqbal M. 2019. A global perspective on H9N2 avian influenza virus. Viruses 11(7):620 DOI 10.3390/v11070620.

Peiris JS, de Jong MD, Guan Y. 2007. Avian influenza virus (H5N1): a threat to human health. Clinical Microbiology Reviews 20(2):243-67 DOI 10.1128/CMR.00037-06.

Powell TJ, Fox A, Peng Y, Quynh Mai Le T, Lien VT, Hang NL, Wang L, Lee LY, Simmons CP, McMichael AJ, Farrar JJ, Askonas BA, Duong TN, Thai PQ, Thu Yen NT, Rowland-Jones SL, Hien NT, Horby P, Dong T. 2012. Identification of H5N1-specific T-cell responses in a high-risk cohort in Vietnam indicates the existence of potential asymptomatic infections. The Journal of Infectious Diseases 205(1):20-7 DOI 10.1093/infdis/jir689.

Puthavathana P, Auewarakul P, Charoenying PC, Sangsiriwut K, Pooruk P, Boonnak K, Khanyok R, Thawachsupa P, Kijphati R, Sawanpanyalert P. 2005. Molecular
characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. *Journal of General Virology* **86**(Pt 2):423-33 DOI 10.1099/vir.0.80368-0.

Puzelli S, Rossini G, Facchini M, Vaccari G, Di Trani L, Di Martino A, Gaibani P, Vocale C, Cattoli G, Bennett M, McCauley JW, Rezza G, Moro ML, Rangoni R, Finarelli AC, Landini MP, Castrucci MR, Donatelli I; Influenza Task Force. 2014. Human infection with highly pathogenic A(H7N7) avian influenza virus, Italy, 2013. *Emerging Infectious Diseases* **20**(10):1745-9 DOI 10.3201/eid2010.140512.

Richards KA, Chaves FA, Sant AJ. 2009. Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus. *Journal of Virology* **83**(13):6566-77 DOI 10.1128/JVI.00302-09.

Rimmelzwaan GF, Boon AC, Voeten JT, Berkhoff EG, Fouchier RA, Osterhaus AD. 2004. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. *Virus Research* **103**(1-2):97-100 DOI 10.1016/j.virusres.2004.02.020.

Rimmelzwaan GF, Katz JM. 2013. Immune responses to infection with H5N1 influenza virus. *Virus Research* **178**(1):44-52 DOI 10.1016/j.virusres.2013.05.011.

Ross KA, Loyd H, Wu W, Huntimer L, Ahmed S, Sambol A, Broderick S, Flickinger Z, Rajan K, Bronich T, Mallapragada S, Wannemuehler MJ, Carpenter S, Narasimhan B. 2014. Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity. *International Journal of Nanomedicine* **10**:229-43 DOI 10.2147/IJN.S72264.
Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. 2008. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. *Journal of Immunology* **180**(3):1758-68 DOI 10.4049/jimmunol.180.3.1758.

Sawai T, Itoh Y, Ozaki H, Isoda N, Okamoto K, Kashima Y, Kawaoka Y, Takeuchi Y, Kida H, Ogasawara K. 2008. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. *Immunology* **124**(2):155-65 DOI 10.1111/j.1365-2567.2007.02745.x.

Seo SH, Webster RG. 2001. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. *Journal of Virology* **75**(6):2516-25 DOI 10.1128/JVI.75.6.2516-2525.2001.

Seo SH, Peiris M, Webster RG. 2002. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. *Journal of Virology* **76**(10):4886-90 DOI 10.1128/jvi.76.10.4886-4890.2002.

Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, Gao B, Tien P, Shu Y, Iwamoto A, Chen Z, Gao GF. 2010. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. *Journal of General Virology* **91**(Pt 4):919-30 DOI 10.1099/vir.0.016766-0.

Taubenberger JK, Kash JC. 2010. Influenza virus evolution, host adaptation, and pandemic formation. *Cell Host & Microbe* **7**(6):440-51 DOI 10.1016/j.chom.2010.05.009.

Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. 2006. Cell-mediated protection in influenza infection. *Emerging Infectious Diseases* **12**(1):48-54 DOI 10.3201/eid1201.051237.
Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmerman JM, Chunsutthiwat S. 2005. Probable person-to-person transmission of avian influenza A (H5N1). *The New England Journal of Medicine* **352**(4):333-40 DOI 10.1056/NEJMoa044021.

van Maurik A, Sabarth N, Dacho HS, Brühl P, Schwendinger M, Crowe BA, Noel Barrett P, Kistner O, Keith Howard M. 2010. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. *Vaccine* **28**(7):1778-85 DOI 10.1016/j.vaccine.2009.12.008.

Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. 1992. Evolution and ecology of influenza A viruses. *Microbiology Reviews* **56**(1):152-79 PMID 1579108.

Wong SS, Yuen KY. 2006. Avian influenza virus infections in humans. *Chest* **129**(1):156-68 DOI 10.1378/chest.129.1.156.

World Health Organization (WHO). 2020. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. Available at https://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/. (Accessed 12 September 2020).

Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM. 2008. Update on avian influenza A (H5N1) virus infection in humans. *The New England Journal of Medicine* **358**(3):261-73 DOI 10.1056/NEJMra0707279.
Yu H, Cowling BJ, Feng L, Lau EH, Liao Q, Tsang TK, Peng Z, Wu P, Liu F, Fang VJ, Zhang H, Li M, Zeng L, Xu Z, Li Z, Luo H, Li Q, Feng Z, Cao B, Yang W, Wu JT, Wang Y, Leung GM. 2013. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. *Lancet* **382**(9887):138-45 DOI 10.1016/S0140-6736(13)61207-6.

Zhao Y, Zhang YH, Denney L, Young D, Powell TJ, Peng YC, Li N, Yan HP, Wang DY, Shu YL, Kendrick Y, McMichael AJ, Ho LP, Dong T. 2012. High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection. *American Journal Respiratory and Critical Care Medicine* **186**(12):1292-7 DOI 10.1164/rccm.201207-1245OC.
Table 1 (on next page)

Magnitude of cross-reactive T cell responses to H5N1 NP peptides in non-H5N1 subjects
Table 1. Magnitude of cross-reactive T cell responses to H5N1 NP peptides in non-H5N1 subjects

| Subject No. | Peptide | Amino acid sequence                  | ex vivo IFN-γ response (SFCs/10^6 PBMCs) |
|-------------|---------|--------------------------------------|----------------------------------------|
| H3N2 patients (six responders from 10 patients, 60%) |
| 2           | NP<sub>111-130</sub> | YDKEEIRRIWRQANNGEDAT                   | 40                                     |
| 6           | NP<sub>221-240</sub> | RMCNILKGKFQTAQRAMMD                    | 140                                    |
| 7           | NP<sub>111-130</sub> | YDKEEIRRIWRQANNGEDAT                   | 60                                     |
| 8           | NP<sub>221-240</sub> | RMCNILKGKFQTAQRAMMD                    | 62                                     |
|             | NP<sub>311-330</sub> | QVFSLRPNENPAHKSQVLW                    | 104                                    |
| 9           | NP<sub>221-240</sub> | RMCNILKGKFQTAQRAMMD                    | 104                                    |
| 10          | NP<sub>311-330</sub> | QVFSLRPNENPAHKSQVLW                    | 105                                    |
| Healthy individuals (nine responders from 23 subjects, 39%) |
| 11          | NP<sub>481-498</sub> | MNNEGSYFFGDNAEYEYDN                    | 36                                     |
|             | NP<sub>311-330</sub> | QVFSLRPNENPAHKSQVLW                    | 52                                     |
| 13          | NP<sub>221-240</sub> | RMCNILKGKFQTAQRAMMD                    | 37                                     |
|             | NP<sub>111-130</sub> | YDKEEIRRIWRQANNGEDAT                   | 28                                     |
| 17          | NP<sub>111-130</sub> | YDKEEIRRIWRQANNGEDAT                   | 32                                     |
| 19          | NP<sub>481-498</sub> | MNNEGSYFFGDNAEYEYDN                    | 22                                     |
| 27          | NP<sub>111-130</sub> | YDKEEIRRIWRQANNGEDAT                   | 53                                     |
| 28          | NP<sub>481-498</sub> | MNNEGSYFFGDNAEYEYDN                    | 28                                     |
| 29          | NP<sub>221-240</sub> | RMCNILKGKFQTAQRAMMD                    | 71                                     |
| 30          | NP<sub>401-420</sub> | ASAGQISVQPTFSVQRNLPF                   | 45                                     |
| 31          | NP<sub>221-240</sub> | RMCNILKGKFQTAQRAMMD                    | 37                                     |
|             | NP<sub>401-420</sub> | ASAGQISVQPTFSVQRNLPF                   | 64                                     |
Table 2 (on next page)

Amino acid identity and cross reactivity to H5N1 NP peptides
Table 2. Amino acid identity and cross reactivity to H5N1 NP peptides

| Epitope / subtype | Sequence | Cross reactivity | Frequency of recognition |
|-------------------|----------|-----------------|--------------------------|
| NP1-20            |          | -               | 1* survivor              |
| H5                | MASQGTKRSYEQMETGGERQ |               |                          |
| H3                | ***************D*D**  |               |                          |
| H1                | ***************D****   |               |                          |
| H1pdm             | ***************       |               |                          |
|                   | NP111-130         |                |                          |
| H5                | YDKEEIRRIWRQANNGEDAT | +            | 5 (1* survivor)         |
| H3                | ******************   |               |                          |
| H1                | ******************D***|               |                          |
| H1pdm             | ******************V*  |               |                          |
|                   | NP221-240          |                |                          |
| H5                | RMCNILKGFQTAQRAMMD  | +            | 6                        |
| H3                | ******************   |               |                          |
| H1                | ******************K***|               |                          |
| H1pdm             | ******************V*  |               |                          |
|                   | NP311-330          |                |                          |
| H5                | QVFSLIRPNENPAHKSQLVW| +            | 3                        |
| H3                | *IY*****************|               |                          |
| H1                | *VY*****************|               |                          |
| H1pdm             | *****M************* |              |                          |
|                   | NP401-420          |                |                          |
| H5                | ASAGQISVQPTFSVQRNLFF| +            | 2                        |
| H3                | *****T*************|               |                          |
| H1                | *****T*************|               |                          |
| H1pdm             | *****************    |               |                          |
|                   | NP411-430          |                |                          |
| H5                | TFSVQRNLPPFERATIMAAFT| -          | 1* survivor              |
| H3                | **********KS******   |               |                          |
| H1                | **********DKT*******|               |                          |
| H1pdm             | ******************S  |               |                          |
|                   | NP481-498          |                |                          |
| H5                | MNNEGSYFFGDNAEYDN   | +            | 3                        |
| H3                | *S***************** |               |                          |
| H1                | *S***************** |               |                          |
| H1pdm             | *S***************** |               |                          |

Note * H5N1 survivor subject
- NP from H5N1 strain A/Thailand/1(KAN-1)/2004 (H5N1) (accession no. AAV35112); H3N2 strain A/Brisbane/10/2007 (H3N2) (accession no. ACO95274); H1N1 strain A/New Caledonia/20/1999 (H1N1) (accession no. ABW81621); H1N1pdm strain A/Thailand/104/2009 (H1N1) (accession no. ACR23306)
- Cross reactivity: (-) epitope recognized by H5N1 survivor only; (+) epitope recognition by H5N1 survivor and/or non-H5N1 subjects
Figure 1

Total magnitude of T cell responses against H5N1 NP, M and HA peptides in sequential PBMC samples from four H5N1 survivors as measured by IFN-γ ELISpot assay.

The IFN-γ producing T cells against H5N1 overlapping peptides of NP (A), M (B) and HA (C) are indicated. Survivor nos.1 and 2 had higher magnitude of T cell responses against NP and M peptides than survivor nos. 3 and 4.
A) Ex vivo IFN-γ response (SFCs/10⁶ PBMCs)

B) Ex vivo IFN-γ response (SFCs/10⁶ PBMCs)

C) Ex vivo IFN-γ response (SFCs/10⁶ PBMCs)
Figure 2

*Ex vivo* IFN-γ responses and longevity of H5N1 virus-specific T cells against NP, M and HA individual peptides in H5N1 survivors.

The responses of peptide-specific T cells of survivor no. 1 (A) and survivor no. 2 (B) are shown as determined by IFN-γ ELISpot assay.
Figure 3

Total magnitude of IFN-γ cross-reactive T cell responses in H3N2 patients and healthy individuals.

There was statistically significant difference in mean of magnitude of responses (SFCs/10^6 PBMCs) between two groups (Mann-Whitney U test $p<0.05$).
Figure 4

Polyfunctional analysis of effector NP\textsubscript{411-430}-specific T cells.

The T cell function which singly or simultaneously produced IFN-γ and TNF-α (A) and/or upregulation of CD107a degranulation marker (B) in survivor no. 2 are shown. The percentages of both specific CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells that expressed IFN-γ\textsuperscript{+}, TNF-α\textsuperscript{+} and/or CD107a markedly increased in recognition of the target cells pulsed with peptide or infected with rVac-NP virus.
